Skip to main content
Clinical Trials/JPRN-UMIN000048096
JPRN-UMIN000048096
Completed
未知

A multicenter retrospective observational study evaluating the safety and efficacy of immune checkpoint inhibitors in patients with advanced or recurrent lung cancer after COVID-19 vaccination (NEJ061) - NEJ061 study

Specified Nonprofit Corporation North East Japan Study Group0 sites850 target enrollmentJune 18, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
advanced or recurrent lung cancer
Sponsor
Specified Nonprofit Corporation North East Japan Study Group
Enrollment
850
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 18, 2022
End Date
July 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Specified Nonprofit Corporation North East Japan Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. active concomitant malignancy 2\. interstitial pneumonia or pulmonary fibrosis detectable on CT scan 3\. re\-administration of immune checkpoint inhibitors (previously PD or toxic discontinuation) 4\. with active hepatitis B or hepatitis C 5\. with autoimmune disease or a history of autoimmune disease requiring steroid therapy 6\. other than autoimmune diseases, continuous systemic or intravenous administration of steroids at doses higher than 10 mg / day in terms of prednisolone is required, and immunosuppressants are used 7\. with a history of human immunodeficiency virus

Outcomes

Primary Outcomes

Not specified

Similar Trials